1. Home
  2. NUVB vs OFIX Comparison

NUVB vs OFIX Comparison

Compare NUVB & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • OFIX
  • Stock Information
  • Founded
  • NUVB 2018
  • OFIX 1987
  • Country
  • NUVB United States
  • OFIX United States
  • Employees
  • NUVB N/A
  • OFIX N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • OFIX Medical/Dental Instruments
  • Sector
  • NUVB Health Care
  • OFIX Health Care
  • Exchange
  • NUVB Nasdaq
  • OFIX Nasdaq
  • Market Cap
  • NUVB 837.0M
  • OFIX 562.8M
  • IPO Year
  • NUVB N/A
  • OFIX N/A
  • Fundamental
  • Price
  • NUVB $3.14
  • OFIX $14.93
  • Analyst Decision
  • NUVB Strong Buy
  • OFIX Strong Buy
  • Analyst Count
  • NUVB 6
  • OFIX 5
  • Target Price
  • NUVB $8.17
  • OFIX $21.50
  • AVG Volume (30 Days)
  • NUVB 6.6M
  • OFIX 456.4K
  • Earning Date
  • NUVB 11-05-2025
  • OFIX 11-06-2025
  • Dividend Yield
  • NUVB N/A
  • OFIX N/A
  • EPS Growth
  • NUVB N/A
  • OFIX N/A
  • EPS
  • NUVB N/A
  • OFIX N/A
  • Revenue
  • NUVB $14,355,000.00
  • OFIX $809,030,000.00
  • Revenue This Year
  • NUVB $332.80
  • OFIX $3.86
  • Revenue Next Year
  • NUVB $360.12
  • OFIX $5.57
  • P/E Ratio
  • NUVB N/A
  • OFIX N/A
  • Revenue Growth
  • NUVB 900.35
  • OFIX 4.84
  • 52 Week Low
  • NUVB $1.54
  • OFIX $10.24
  • 52 Week High
  • NUVB $4.09
  • OFIX $20.73
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 53.76
  • OFIX 63.21
  • Support Level
  • NUVB $3.20
  • OFIX $14.21
  • Resistance Level
  • NUVB $3.44
  • OFIX $15.42
  • Average True Range (ATR)
  • NUVB 0.26
  • OFIX 0.43
  • MACD
  • NUVB -0.02
  • OFIX -0.10
  • Stochastic Oscillator
  • NUVB 20.73
  • OFIX 51.65

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Share on Social Networks: